drugset / Trial / NCT02557789

Bioavailability and Pharmacokinetics of Lefamulin When Administered to Fed and Fasted Healthy Subjects

NCT02557789

Phase 1 Completed 20 enrolled Nabriva Therapeutics AG
RandomizedCrossoverOpen-label

Summary

A Phase 1 study to assess the bioavailability and pharmacokinetics of a 600 mg immediate release tablet formulation of lefamulin when administered to fed and fasted healthy subjects in comparison to an intravenous formulation and a capsule formulation.

Timeline

Start
2015-06
Primary completion
2015-06
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Lefamulin Other / unclassified 150 mg Oral
Subject Lefamulin Other / unclassified 600 mg Oral

Indications

No indication recorded.